Vilin Bio Med Ltd IPO
IPO Timeline
Category-wise Subscription
| Category | Sub (x) | Offered | Bid For | Amt (Cr)* |
|---|---|---|---|---|
| NII (HNI) | — | 1,896,000 (47%) | — | ₹569 Cr |
| Retail | — | 1,896,000 (47%) | — | ₹569 Cr |
| Market Maker | — | 208,000 (5%) | — | ₹6 Cr |
| Σ Total | — | 4,000,000 (100%) | — | ₹12,000 Cr |
Only available investor categories are shown. Amount is auto-calculated when shares offered and issue price are available.
Issue Details
Minimum Investment (Lot-wise)
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 4,000 | ₹120,000 |
| Retail (Max) | 13 | 52,000 | ₹1,560,000 |
| S-HNI (Min) | 14 | 56,000 | ₹1,680,000 |
| B-HNI (Min) | 67 | 268,000 | ₹8,040,000 |
Financial Statements Amount in ₹ Lakhs
| Metric | 31-Dec-22 | 31-Mar-22 | 31-Mar-21 |
|---|---|---|---|
| Revenue | 903 | 1,122 | 1,172 |
| Profit After Tax | 1,172 | 3 | 12 |
| Net Worth | 868 | 740 | 736 |
| Total Assets | 1,687 | 1,356 | 1,389 |
| Reserves & Surplus | 538 | 410 | 406 |
| Total Borrowing | 618 | 530 | 552 |
Valuation & Key Ratios
Grey Market Premium (GMP)
GMP is an unofficial grey market indicator and does not guarantee actual listing price. Invest at your own risk.
Objects of the Issue
- Augmenting additional working capital requirements – 8.49
- General Corporate Purposes – 2.51
Company Overview
Incorporated in 2005, Vilin Bio Med Limited is engaged in the domestic business of manufacturing pharmaceutical products, and the manufacturing unit.
The company sells its products in bulk to pharmaceutical manufacturers, marketers, and traders, who provide the channel for sales to customers.
Its product list can be classified into:
- Oral Liquid (Syrups/Suspensions/Dry Powders (βeta & Non-βeta-Lactam).
- Tablets & Capsules (βeta & Non-βeta-Lactam).
- External Preparations.
- Dry Powders.
The company has its R&D foundation and manufacturing facility in Roorkee, Uttarakhand.
Vilin Bio Med recorded a Rs. 1,121.91 Lakhs revenue in the year 2022, and Rs. 1,171.88 Lakhs in the year 2021.